Treatment and prevention of experimental autoimmune myocarditis with CD28 superagonists

Cardiology

Volumn 115, Issue 2, 2010, Pages 107-113

  Wang, Shu ^a   Liu, Jing ^a   Wang, Min ^a   Zhang, Jinghui ^a   Wang, Zhaohui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CD28 superagonists; CD4+CD25+; Dilated cardiomyopathy; Experimental autoimmune myocarditis; Foxp3; IL 10; Myocarditis; Treg cells

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; JJ 316; MONOCLONAL ANTIBODY CD28; MYOSIN; MYOSIN ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG MECHANISM; DRUG TARGETING; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; IMMUNIZATION; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; AUTOIMMUNE DISEASES; CARDIAC MYOSINS; CARDIOMYOPATHY, DILATED; FORKHEAD TRANSCRIPTION FACTORS; MALE; MYOCARDITIS; RATS; RATS, INBRED LEW; SWINE; T-LYMPHOCYTES, REGULATORY;

EID: 70449513125     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000256660     Document Type: Article

References (28)

1. Afanasyeva M, Wang Y, Kaya Z: Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001; 159: 193-203.
2. Fu M, Matsui S: Is cardiomyopathy an autoimmune disease? Keio J Med 2002; 51: 208-212.
3. Toda A, Piccirillo CA: Development and function of naturally occurring CD4+CD25+ regulatory T cells J Leukoc Biol 2006; 80: 458-470.
4. Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562. (Pubitemid 38680433)
5. Taylor PA, Noelle RJ, Blazar BR: CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001; 193: 1311-1318.
6. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
7. Jaeckel E, von Boehmer H, Manns MP: Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 2005; 54: 306-310.
8. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000,12: 431-440.
9. Tacke M, Hanke G, Hanke T, Hünig T: CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27: 239-247.
10. Karin E, Marta R, Thomas K, Thomas H: Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood 2003; 102: 1764-1770.
11. Rodriguez-Palmero M, Hara T, Thumbs A, Hünig T: Triggering of T-cell proliferation through CD28 induces GATA-3 and promotes T-helper type 2 differentiation in vitro and in vivo. Eur J Immunol 1999,29: 3914-3924.
12. Beyersdorf N, Gaupp S, Balbach K, et al: Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202: 445-455.
13. Tischner D, Weishaupt A, van den Brandt J, et al: Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 2006; 129: 2635-2647.
14. Afanasyeva M, Gerogakopoulos D, Rose NR: Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Autoimmun Rev 2004; 3: 476-486.
15. Kamiyoshi Y, Takahashi M, Yokoseki O, et al: Mycophenolate mofetil prevents the development of experimental autoimmune myocarditis. J Mol Cell Cardiol 2005: 39: 467-477.
16. Werner L, Deutsch V, Barshack I, et al: Transfer of endothelial progenitor cells improves myocardial performance in rats with dilated cardiomyopathy induced following experimental myocarditis. J Mol Cell Cardiol 2005; 39: 691-697.
17. George J, Barshack I, Goldberg I, Keren P, Gazit A, Levitzki A, Keren G, Roth A: The effect of early and late treatment with the tyrphostin AG-556 on the progression of experimental autoimmune myocarditis. Exp Mol Pathol 2004; 76: 234-241.
18. Wang Y, Afanasyeva M, Hill SL, Rose NR: Characterization of murine autoimmune myocarditis induced by self and foreign cardiac myosin. Autoimmunity 1999; 31: 151-162.
19. Wang Y, Afanasyeva M, Hill SL, Kaya Z, Rose NR: Nasal administration of cardiac myosin suppresses autoimmune myocarditis in mice. J Am Coll Cardiol 2000; 36: 1992-1999.
20. Kaya Z, Afanasyeva M, Wang Y: Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2001; 2: 739-745.
21. Liu PP, Mason JW: Advances in the understanding of myocarditis. Circulation 2001; 104: 1076-1082.
22. Penninger JM, Pummerer C, Liu P, et al: Cellular and molecular mechanisms of murine autoimmune myocarditis. J APMIS 1997; 105: 1-13.
23. Ono M, Shimizu J, Miyachi Y, et al: Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25+ and CD25-regulatory T cells. J Immunol 2006; 176: 4748-4756.
24. Zhao DM, Thornton AM, Dipaolo RJ, et al: Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006; 107: 3925-3932.
25. Li Y, Heuser JS, Kosanke SD, et al: Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cells. Am J Pathol 2005; 167: 5-15.
26. Futamatsu H, Suzuki J, Mizuno S, et al: Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. Circ Res 2005; 96: 823-830.
27. Zhao P, Su G, Xiao X, et al: Chinese medicinal herb Radix Astragali suppresses cardiac contractile dysfunction and inflammation in a rat model of autoimmune myocarditis. Toxicol Lett 2008; 182: 29-35.
28. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.